Research Article

Tuberculosis Treatment Outcomes and Associated Factors among TB Patients Attending Public Hospitals in Harar Town, Eastern Ethiopia: A Five-Year Retrospective Study

Assefa Tola,1 Kirubel Minsamo Minshore,2 Yohanes Ayele,2 and Abraham Nigussie Mekuria3

1Department of Epidemiology and Biostatistics, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
2Department of Clinical Pharmacy, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
3Department of Pharmacology, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia

Correspondence should be addressed to Assefa Tola; asseharar@yahoo.com

Received 4 September 2018; Revised 22 January 2019; Accepted 21 February 2019; Published 1 April 2019

Academic Editor: Vincent Jarlier

Copyright © 2019 Assefa Tola et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Tuberculosis remains a major public health threat throughout the world particularly in developing countries. Evaluating the treatment outcome of tuberculosis and identifying the associated factors should be an integral part of tuberculosis treatment. Objectives. The aim of this study was to assess the treatment outcome of tuberculosis and its associated factors among TB patients in the TB clinics of Harar public hospitals, Eastern Ethiopia, 2017. Methods. A retrospective document review was conducted in two public hospitals of Harar town, located 516 km east of Addis Ababa. A systematic random sampling technique was used to select the document of TB patients who were registered in the hospitals from 1st of January, 2011, to 30th of December, 2015. The data were collected using a pretested structured data extraction format. SPSS Version 21 for window was used for data processing. Bivariate and multivariate analysis with 95% confidence interval was employed in order to infer the associations between TB treatment outcome and potential predictor variables. Results. One thousand two hundred thirty-six registered TB patients’ documents were reviewed. Of these, 59.8% were male, 94.2% were urban dwellers, 97% were new cases, 61.2% were presented with pulmonary TB, and 22.8% were HIV positive. Regarding the treatment outcome, 30.4% were cured, 62.1% completed their treatment, 3.9% died, 2.4% were defaulted, and the remaining 1.2% had failed treatment. The overall rate of the treatment success among the patients was 92.5%. In the present study, being female (AOR = 1.89, 95% CI: 1.14 - 3.14), having pretreatment weight of 20 – 29 kg (AOR = 11.03, 95% CI: 1.66 - 73.35), being HIV negative (AOR = 6.50, 95% CI: 3.95 - 10.71), and being new TB patient (AOR = 3.22 95% CI: 1.10 - 9.47) were factors independently associated with successful treatment outcome. On the other hand, being in the age group 54 – 64 years (AOR =10.41, 95% CI: 1.86 - 58.30) and age greater than 65 years (AOR =24.41, 95% CI: 4.19 - 142.33) was associated with unsuccessful TB treatment outcome. Conclusion. In the current study, the rate of successful TB treatment outcome was acceptable. This rate should be maintained and further improved by designing appropriate monitoring strategies.

1. Introduction

Tuberculosis [1] remains a major public health threat throughout the world, developing countries shouldering much of the burden. According to the WHO report, TB is the ninth leading cause of death worldwide and it is also a leading cause of death among infectious agents, ranking above HIV/AIDS. In 2016 alone an estimated 10.4 million people fell ill with TB, of whom Africa accounted 74% cases and around 1,674,000 TB deaths were recorded globally.

According to WHO TB report, 20 countries share 85% of all estimated TB cases worldwide and Ethiopia falls under this category indicating high TB burden in the country [2]. Although the incidence of infection with TB is decreasing and there has been a positive move toward its management, more effort is needed to meet End TB Strategy, which aims at
reducing the death rate by 90% by the year 2030, compared with 2015 [2, 3].

TB epidemiology is closely connected with social and economic conditions which make its prevention, care, and control more challenging [4, 5]. Many of the TB related morbidities are preventable by early diagnosis and appropriate treatment; however, owing to various reasons, its management is not always that easy [4, 5]. Evaluating the treatment outcome of TB and identifying its associated factors is an integral part of the treatment. Although the rate of the successful treatment outcome of the disease varies from country to country, 83% has been reported globally [2].

Studies conducted in various parts of Ethiopia reported different success rates of the treatment and the associated factors. For instance, a study conducted in the Northern part of the country reported 89.2% [6], but another study in the same region reported only 60.1% [7]. In the prior study, it was indicated that age greater than 40 years, family size greater than five, and being a retreatment case were strongly associated with unsuccessful treatment outcomes whereas coinfection with HIV and being male were associated with unsuccessful treatment outcomes in a later study.

Undoubtedly, the success rate of TB treatment outcome and the associated factors vary from setting to setting. Routine monitoring of the extent of the outcome and its determinants is important, but studies that have focused on TB treatment outcome and factors associated with unsuccessful treatment outcomes ina later study. It was indicated that age greater than 40 years, family size greater than five, and being a retreatment case were strongly associated with unsuccessful treatment outcomes whereas coinfection with HIV and being male were associated with unsuccessful treatment outcomes in a later study.

The objective of the study is to assess TB treatment outcome and associated factors among TB patients in Public Hospitals of Harar town, Eastern Ethiopia. Therefore, the aim of this study was to assess TB treatment outcome and factors associated among TB patients in Public Hospitals of Harar town, Eastern Ethiopia.

The study was conducted to assess TB treatment outcome and factors associated among TB patients in Public Hospitals of Harar town, Eastern Ethiopia, 2017.

2. Methods and Materials

2.1. Study Area and Period. This study was conducted in two public hospitals (Hiwot Fana Specialized University Hospital and Jugal Hospital) in Harar town. The data were collected from April 24 to 29, 2017.

2.2. Study Design and Data Collection. A retrospective document review was conducted to assess the treatment outcome of TB patients and the associated factors from TB patients’ documents registered from January 1, 2011, to December 31, 2015, at Public hospitals in Harar town.

2.3. Source Population. The documents of all the TB patients who were registered in the two public hospitals from 1st of January, 2011, to December 31st, 2015, were the source population.

2.4. Study Population. The documents of the randomly selected TB patients who were registered in the two public hospitals from 1st of January, 2011, to December 31st, 2015, were the study population.

2.5. Inclusion and Exclusion Criteria. The documents of all the registered TB patients at two public hospitals were included in this study.

However, registries in which treatment outcomes were missing and patients were transferred to other districts were excluded from the study.

2.6. Sample Size Determination. The sample size was determined by using double population proportions formula.

\[
n = \frac{(z_{a/2} + z_{\beta})^2 \times 2p(1 - p)}{(p_1 - p_2)^2}
\]

where \( n \) = sample size for each group

\[Z_{\alpha/2} = \text{the desired level of statistical significance: } 95\% \implies 1.96\]

\[Z_{\beta} = \text{the desired power: } 80\% \text{ power } \implies 0.84\]

\[P_1 = \text{proportions of good/poor treatment outcome among the nonexposed}\]

\[P_2 = \text{proportions of good/poor treatment outcome among the exposed}\]

\[p_1 - p_2 = \text{the difference in proportions of good/poor treatment outcome among the nonexposed and exposed}\]

\[P = (p_1 + p_2)/2\]

By using the above formula

(1) cure rate among HIV negative and HIV positive TB patients

\[Z_{\alpha}=95\% \ Z_{\beta}= 80\%, \ r=1, \ P_1=85\., \ P_2=55.7\% \ n=74\]

(2) cure rate among male and female TB patients

\[Z_{\alpha}=95\% \ Z_{\beta}= 80\%, \ r=2, \ P_1=4.3\% \ P_2=8.6\% \ n=1026\]

(3) Cure rate among male and female TB patients

\[Z_{\alpha}=95\% \ Z_{\beta}= 80\%, \ r=2, \ P_1=3.6 \% \ P_2=7.2 \% \ n=1236\]

From the above options, the largest sample size (1236) was selected [8].

2.7. Sampling Technique. Totally 3329 TB patients registered during the review period, from January 1st, 2011, to December 31st, 2015, in two public hospitals (1535 in Jugal Hospital and 1794 in Hiwot Fana).

The sample size (1236) was distributed to each clinic using a proportionate allocation. Therefore, a total sample size for each TB clinic was

Jugal Hospital TB clinic = \( \frac{N_1}{N} \times n = \frac{1535}{3329} \times 1236 \)

= 570

Hiwot Fana Specialized University Hospital TB clinic

\[= \frac{N_1}{N} \times n = \frac{1794}{3329} \times 1236 = 666\]
From each TB clinic, registry which met the inclusion criteria was selected through a systematic sampling technique. This sampling interval (K) was obtained by dividing the total TB patients in each hospital to its sample size (k = 1869/940 = 1.99 ∼2 for Hiwot Fana Hospital and 1460/734 = 1.99 ∼2 for Jugol Hospital). The 1st sample was taken by lottery method from 1 and 2; then the data were collected, every other registration number at both sites.

2.8. Data Collection. The data were collected by using a pretested structured data extraction format. The standard TB registry, laboratory findings, and monthly cohort follow-up form were reviewed to generate the required data. The standardized checklist used included all important sociodemographic data, clinical characteristics (sputum smear, type of TB, patient type, HIV status, drug regimen, and treatment outcomes), laboratory findings, and follow-up data. Data was collected by four BSc. nurses who have had training on comprehensive TB care and experience in data collection.

2.9. Statistical Analysis. Data were entered, cleaned, and analyzed using SPSS Version 21 for windows. Appropriate descriptive statistics such as mean (with standard deviation), median (with inter quartile range [IQR]), and frequencies (with percentages) were used to describe the study population in relation to relevant variables.

Bivariate and multivariate analysis with 95% confidence interval was employed to infer associations between the independent and dependent variables.

Binary logistic regression was used to calculate the crude odds ratio (COR) with 95% confidence interval. Each variable was entered into a logistic regression model so as to determine the presence of statistical significant association with the outcome variable. Multicollinearity among selected independent variables was checked through variance inflation factor (VIF) and none was found. All the explanatory variables with a $P \leq 0.2$ in the bivariate analyses were included in the final multivariable logistic model in order to identify the independent predictors of TB treatment outcome. A $P$ value $< 0.05$ was considered statistically significant. Assumption on fitness of goodness of the final model was checked by Hosmer and Lemeshow test and was found fit.

2.10. Ethical Statement. Ethical approval was obtained from research review technical committee of Harar health Science College. A legal authorization letter was written from Harar health Science College to study settings to get permission before data collection. The information obtained was made anonymous and deidentified prior to analysis to ensure confidentiality.

2.11. Operational Definitions. In this study, treatment outcomes are categorized into successful and unsuccessful treatment outcomes.

Successful treatment outcome included “cured” and “treatment completed” cases.

Unsuccessful treatment outcome included “treatment failure” cases, “defaulter,” and patients who “died.”

According to the WHO, Treatment Outcomes Were Categorized into the following.

Successful outcome: if the TB patients were cured (negative smear microscopy at the end of the treatment and on at least one previous follow-up test) or completed treatment with resolution of symptoms.

Unsuccessful outcome: if the treatment resulted in treatment failure (remaining smear positive after 5 months of treatment), patients are default (patients who interrupted their treatment for two consecutive months or more after registration), or patients died.

According to the standard definitions of the National Tuberculosis and Leprosy Control Program guidelines of Ethiopia (NTLCP)[9], the following definitions were used for treatment outcome.

Cured: if the patients had finished treatment with negative bacteriological result at the end of the treatment.

Treatment completed: if the patients had finished treatment, but without bacteriological result at the end of the treatment.

Treatment failure: a patient who, while on treatment, remained smear positive or became again smear positive at the end of the five months or later, after commencing treatment or a patient who was PTB-negative at the beginning and turned out smear positive at the end of the intensive phase.

Defaulter: a patient who had been on treatment for at least 4 weeks and whose treatment was interrupted for 8 or more consecutive weeks.

Died: if the patient died from any cause during the course of the treatment.

New case: a patient who had never had treatment for TB or had been on anti-TB treatment for less than four weeks.

Three types of TB were considered in this study. These were smear positive pulmonary TB (PTB+), smear negative pulmonary TB (PTB-), and extra-pulmonary TB (EPTB).

Smear positive pulmonary TB (PTB+): a patient who had at least 2 initial smear examinations positive for AFB by direct microscopy or one initial smear examination positive and culture positive or one initial smear positive and radiographic abnormalities consistent with TB.

Smear negative pulmonary TB (PTB-): a patient who had three initial smear examinations negative for AFB and no response to course of broad-spectrum chemotherapy and again 3 smear examinations negative by direct microscopy and radiographic abnormalities consistent with PTB and three initial smear examinations negative by direct microscopy but positive by culture and decision by a clinician to treat with anti-TB.
3. Results

3.1. Sociodemographic Characteristics. The documents of 1236 TB patients were reviewed in this study. More than half of these TB patients (59.8%) were male, with male-to-female ratio of 1.5 to 1. Their age ranged from 1 to 95 years, with a median of 29 years (IQR: 22 - 40 years). About 363 (29.4%) of the participants were in the age range of 25–34 years and median of 29 years (IQR: 22 - 40 years). About 363 (29.4%) of these TB patients (59.8%) were male, with male-to-female ratio of 1.5 to 1. Their age ranged from 1 to 95 years, with a median of 29 years (IQR: 22 - 40 years). About 363 (29.4%) of the participants were in the age range of 25–34 years and median of 29 years (IQR: 22 - 40 years).

3.2. Clinical Characteristics of Patients. Most of the attendants (97%) were new TB cases. Seven hundred fifty-six (61.2%) of the patients were presented with pulmonary TB of whom 400 (52.9%) were smear positive. Significant number of the patients 282 (22.8%) were found to be HIV positive of whom 250 (88.7%) and 258 (91.5%) were on ART and Cotrimoxazole Preventive Treatment (CPT), respectively.

Among smear positive PTB patients at the beginning of the treatment, 10 (2.5%), 7 (1.7%), and 14 (3.56%) were smear positive at second, fifth, and seventh months of the treatment, respectively. Most of the (97%) patients were treated with Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol (RHZE) in intensive phase and 86.4% were on Rifampicin and Isoniazid (RH) during the continuation phase (Table 2).

Concerning the trend of all forms of TB, the proportion of extra-pulmonary TB slightly increased from 31.1% in 2011 to 43.3% in 2015 whereas the proportion of smear positive pulmonary TB decreased in the first three years from 40.1% in 2011 to 21.3% in 2013 (Figure 1).

3.3. Treatment Outcome of TB Patients on Anti-TB Therapy. Among the TB patients included in this study, 376 (30.4%) were cured, 767 (62.1%) had completed their treatment, 48 (3.9%) were dead, 30 (2.4%) were defaulted, and the remaining 15 (1.2%) had failed treatment. The cure rate was high in the year 2011 (38.1%) and low in the year 2013 (19.8%). The default rate showed slight increment during the review period, 1.3% in the year 2011 to 3.4% in the year 2015. However, the death rate showed a reduction in the first three years (2011–2013) from 6.1% to 2.0% and then started to increase in the final two years of the study period (2014 and 2015) from 3.3% to 4.4% (Table 3).

3.4. Factors Associated with TB Treatment Outcome. The overall rate of the treatment success (cure and treatment complete) in this study was 92.5%. The rate of treatment success was higher among females (93.8%) than males (91.6%) and patients from rural setting (94.4%) than urban setting (92.4%). The proportion of TB patients with treatment success steadily decreased since 2012 (94.8%), 2013 (93.9%), 2014 (93.0%), and 2015 (90.8%); however, the difference was not statistically significant ($P$ value = 0.429). The treatment success rates were 94.3%, 90.7%, and 92.3% among the PTB+, PTB−, and EPTB patients, respectively. In the bivariate analysis, variables with $P$ value of < 0.2 were sex, age, pretreatment weight, HIV status, patient category, and type of TB (Table 4).

In the multivariable logistic regression; sex, age, pretreatment weight, HIV status, and TB patient category were found to be independently and significantly associated with the treatment outcome. The chance of having successful TB treatment outcome was $1.89$ times higher among the female TB patients ($AOR = 1.89$, 95% CI: 1.140 - 3.135) compared to the male. The HIV negative patients had 6.50 times higher odds of ($AOR = 6.502$, 95%CI: 3.947 - 10.712) having treatment success than the HIV positive. Similarly, the odds of treatment success were 3.22 ($AOR = 3.222$ 95%CI: 1.096 - 9.472) times higher among new TB patients than retreatment TB cases (Table 5).

4. Discussion

Monitoring tuberculosis treatment outcomes and analyzing the responsible factors for unsuccessful treatment have paramount importance to evaluate the effectiveness and efficiency of TB intervention programs. In this study, we aimed to assess TB treatment outcomes and the associated factors in Harar public hospitals, Eastern Ethiopia.

In this study, the majority of the TB cases were male (59.8%). This finding was consistent with previous studies conducted in different areas of Ethiopia (Gimbi (59.3%) [10], Debre Tabor (58.1%) [11], Metema (60%) [12], Gambella (60%) [13], Dilla (61.3%) [14], Afar (62.6%) [15], Southern Ethiopia (57%) [16], Gondar (56%) [7], Hossana (55.3%) [17], Sidama Zone (55%) [18], Tigray (54.3%) [6], and Western Ethiopia (54.3%) [19]) and elsewhere in (Egypt (60.4%) [20], Ibadan Nigeria (55%) [21], South West Nigeria (59%) [22], Ebonyi state of Nigeria (57.7%) [23], and Malaysia (65%)
Table 1: Socio-demographic characteristics of TB patients attending public hospitals of Harar town, Eastern Ethiopia, 2017 (n=1236).

| Variables          | Frequency | Percent |
|--------------------|-----------|---------|
| Sex                |           |         |
| Male               | 739       | 59.8    |
| Female             | 497       | 40.2    |
| Age                |           |         |
| 1 - 14 years       | 68        | 5.5     |
| 15 - 24 years      | 355       | 28.7    |
| 25 - 34 years      | 363       | 29.4    |
| 35 - 44 years      | 205       | 16.6    |
| 45 - 54 years      | 119       | 9.6     |
| 55 - 64 years      | 72        | 5.8     |
| > 64 years         | 54        | 4.4     |
| Place of residence |           |         |
| Urban              | 1164      | 94.2    |
| Rural              | 72        | 5.8     |
| Pretreatment Weight|           |         |
| Less than 20 Kg    | 22        | 1.8     |
| 20 - 29 Kg         | 30        | 2.4     |
| 30 - 37 Kg         | 85        | 6.9     |
| 38 - 54 Kg         | 738       | 59.7    |
| Greater than 54 Kg | 361       | 29.2    |
| Year of treatment  |           |         |
| 2011               | 312       | 25.2    |
| 2012               | 191       | 15.5    |
| 2013               | 197       | 15.9    |
| 2014               | 243       | 19.7    |
| 2015               | 293       | 23.7    |

The higher TB rate among males than the females might be due to the fact that males are more likely either to be exposed to the disease or to utilize health services than the females. Women may also underreport their disease and seek care outside health institutions because of socioeconomic constraints.

The age of the TB patients in this study ranged from 1 to 95 years, with the median age of 29 years and this is also similar to the findings of previous studies [7, 10, 12–14, 16, 18, 19]. Moreover, many of the TB cases we reviewed were between 15 and 34 years of age. This finding indicates that TB affects mainly the productive age group of the society, which can add up on the economic burden of the society particularly in developing countries.

In the present study, 3% of the patients were in the retreatment category. Similar findings were reported in studies conducted in Enfranz (2.4%) [25], Sidama Zone (5%) [18], and Metema (5.7%) [12]. However, it was less than reported from Gimbi (9.9%) [10], Western Ethiopia (8.9%) [19], Debre Tabor (10.9%) [11], Addis Ababa (11.1%) [26], and Gondar (17.5%) [7]. This could be due to the difference in time of the study, study setting, and sample size. Those studies reported the treatment outcome of TB patients before 2013 [7, 11, 19, 26] and were conducted at health centers [11, 19, 26] with smaller sample size [10, 11].

The prevalence of HIV among the patients in this study was 22.8%, which is comparable with the reports from Gambella (26%) [13], Gimbi (23.5) [10], and Metema (20.1%) [12]. However, our finding was higher than previous studies at Hosanna (16.5%) [17], Debre Tabor (12.7%) [11], Enfranz (11.7%) [25], Gondar (13.4%) [7], Iran (2.7%) [27], Dembia (11%) [28], Malaysia (6.6%) [24], Tigray region (8.6%) [6], and Western Ethiopia (17%) [19]. This high TB-HIV coinfection in our study could be due to the higher proportion of patients from urban setting where there is high prevalence of HIV.

More than one-third of the study subjects (38.8%) were presented with extra-pulmonary TB. This finding was comparable with studies from Gimbi (36%) [10], Western Ethiopia (39.7%) [19], Debre Tabor (33.3%) [11], and Addis Ababa (40.1%) [26]. Our finding was also consistent with the report of Ethiopian national population based tuberculosis prevalence survey [29]. This national TB survey stated that the mean (±SD) percentage of extra-pulmonary TB over total notifications from 2000 to 2010 was 34.8% (1.2%). This high proportion of extra-pulmonary TB in Ethiopia might be due high HIV prevalence, over diagnosis or misclassification bias. Furthermore, a similar proportion (32.4%) of TB patients in our study were presented with smear positive pulmonary TB and this is similar with the reports from Metema (30%) [12].
Table 2: Clinical characteristics of TB patients attending public hospitals of Harar town, Eastern Ethiopia, 2017 (n=1236).

| Variables | Frequency | Percent |
|-----------|----------|---------|
| TB clinic |          |         |
| Hiwot Fana SUH | 666 | 53.9    |
| Jugal Hospital | 570 | 46.1    |
| Category of patient | | |
| New case | 1199 | 97.0    |
| Re treatment | 37 | 3.0    |
| Types of TB | | |
| Pulmonary TB | 756 | 61.2    |
| Extra PTB | 480 | 38.8    |
| Smear result (n=756) | | |
| Smear positive | 400 | 52.9    |
| Smear negative | 356 | 47.1    |
| HIV status | | |
| HIV positive | 282 | 22.8    |
| HIV negative | 954 | 77.2    |
| ART initiated (n=282) | | |
| Yes | 250 | 88.7    |
| No | 32 | 11.3    |
| CPT initiated (n=282) | | |
| Yes | 258 | 91.5    |
| No | 24 | 8.5    |
| Smear result after 2 months (n=400) | | |
| Positive | 10 | 2.5    |
| Negative | 390 | 97.5    |
| Smear result after 5 month (n=400) | | |
| Positive | 7 | 1.75    |
| Negative | 393 | 98.25    |
| Smear result after 7 months (n=387) | | |
| Positive | 9 | 2.3    |
| Negative | 378 | 97.7    |
| Anti-TB Drug on Intensive phase | | |
| RHZE | 1199 | 97.0    |
| SERHZ | 37 | 3.0    |
| Anti-TB Drug on continuation phase | | |
| RH | 1068 | 86.4    |
| EH | 168 | 13.6    |

Debre Tabor (28%) [11], Dabat (30%) [30], and Dilla (35.4%) [14].

In the current study, the overall rate of the treatment success of the TB patients was 92.5%, and this is similar to the findings reported from Tigray Region (89%) [6], Dabat (88%) [30], Debre Tabor (87.1%) [11], and Enfraz (95%) [25]. However, it is higher than national report of Ethiopia (84%) [2] and other previous studies in Ethiopia which reported treatment success ranging from 43.3% in Hossana to 85% in Dilla [7, 10, 12–19, 26]. This high treatment success rate in this study might be due to good implementation of DOTs strategy, which was indicated by lower defaulting and treatment failure rates. Another possible explanation could be also due to the exclusion of transfer out patients in this study which was categorized under unsuccessful treatment outcome group in previous studies. In addition, the majority of the TB patients in this study were urban residence; they might have had a better health seeking behavior.

TB associated death rate in present study was 3.9%. This figure was in line with report from Dilla (3.4%) [14], Addis Ababa (3.7%) [26], Afar (4.5%) [15], Enfraz (3.4%) [25], Gambella (3.7%), Dembia (3.3%), Metema (3%), Sidama zone (3.1%), Gimbi (3.7%), Tigray Region (3.9%) [6], Dabat (3.1%) [30], and Hossana (2.9%) [17]. However, some studies reported higher proportion of TB associated death rate, ranging from 5.6% in Debre Tabor and Egypt to 17.7% in Gondar [16, 19, 22, 24, 27, 31].

Defaulting from Anti-TB treatment clinic is one of the main challenges of TB controlling program. The defaulting rate of TB patients from their treatment in this study was
Table 3: Distribution of treatment outcome with socio-demographic and clinical characteristics of TB patients attending public hospitals of Harar town, Eastern Ethiopia, 2017 (n=1236).

| Characteristics          | Treatment outcome | Total |
|--------------------------|-------------------|-------|
|                         | Cure              | Completed | Died | Failure | Defaulted |     |
| **Year of registration**|                   |           |      |         |           |     |
| 2011                     | 119 (38.1%)       | 166 (53.2%) | 19 (6.1%) | 4 (1.3%) | 4 (1.3%) | 312 |
| 2012                     | 62 (32.5%)        | 119 (62.3%) | 4 (2.1%) | 3 (1.6%) | 3 (1.6%) | 191 |
| 2013                     | 39 (19.8%)        | 146 (74.1%) | 4 (2.0%) | 3 (1.5%) | 5 (2.5%) | 197 |
| 2014                     | 78 (32.1%)        | 148 (60.9%) | 8 (3.3%) | 1 (0.4%) | 8 (3.3%) | 243 |
| 2015                     | 78 (26.6%)        | 188 (64.2%) | 13 (4.4%) | 4 (1.4%) | 10 (3.4%) | 293 |
| **Place of residence**   |                   |           |      |         |           |     |
| Urban                    | 359 (30.8%)       | 716 (61.5%) | 48 (4.1%) | 14 (1.2%) | 27 (2.3%) | 1164 |
| Rural                    | 17 (23.6%)        | 51 (70.8%) | 0 (0.0%) | 1 (1.4%) | 3 (4.2%) | 72  |
| **Age group**            |                   |           |      |         |           |     |
| 1 - 14 years             | 12 (17.6%)        | 50 (73.5%) | 4 (5.9%) | 1 (1.5%) | 1 (1.5%) | 68  |
| 15 - 24 years            | 129 (36.3%)       | 213 (60.0%) | 8 (2.3%) | 1 (0.3%) | 4 (1.1%) | 355 |
| 25 - 34 years            | 120 (33.1%)       | 219 (60.3%) | 10 (2.8%) | 4 (1.1%) | 10 (2.8%) | 363 |
| 35 - 44 years            | 60 (29.3%)        | 131 (63.9%) | 6 (2.9%) | 2 (1.0%) | 6 (2.9%) | 205 |
| 45 - 54 years            | 32 (26.9%)        | 75 (63.0%) | 2 (1.7%) | 5 (4.2%) | 5 (4.2%) | 119 |
| 55 - 64 years            | 15 (20.8%)        | 46 (63.9%) | 7 (9.7%) | 2 (2.8%) | 2 (2.8%) | 72  |
| >64 years                | 8 (14.8%)         | 33 (61.1%) | 11 (20.4%) | 0 (0.0%) | 2 (3.7%) | 54  |
| **Sex**                  |                   |           |      |         |           |     |
| Male                     | 241 (32.6%)       | 436 (59.0%) | 27 (3.7%) | 11 (1.5%) | 24 (3.2%) | 739 |
| Female                   | 135 (27.2%)       | 331 (66.6%) | 21 (4.2%) | 4 (0.8%) | 6 (1.2%) | 497 |
| **Pre-treatment weight** |                   |           |      |         |           |     |
| < 20 Kg                  | 2 (9.1%)          | 16 (72.7%) | 2 (9.1%) | 1 (4.5%) | 1 (4.5%) | 22  |
| 20 - 29 Kg               | 3 (10.0%)         | 24 (80.0%) | 2 (6.7%) | 1 (3.3%) | 0 (0.0%) | 30  |
| 30 - 37 Kg               | 28 (32.9%)        | 47 (55.3%) | 5 (5.9%) | 0 (0.0%) | 5 (5.9%) | 85  |
| 38 - 54 Kg               | 232 (31.4%)       | 456 (61.8%) | 29 (3.9%) | 8 (1.1%) | 13 (1.8%) | 738 |
| >55 Kg                   | 111 (30.7%)       | 224 (62.0%) | 10 (2.8%) | 5 (1.4%) | 11 (3.0%) | 361 |
| **HIV status**           |                   |           |      |         |           |     |
| HIV positive             | 73 (25.9%)        | 159 (56.4%) | 25 (8.9%) | 9 (3.2%) | 16 (5.7%) | 282 |
| HIV negative             | 303 (31.8%)       | 608 (63.7%) | 23 (2.4%) | 6 (0.6%) | 14 (1.5%) | 954 |
| **Type of TB**           |                   |           |      |         |           |     |
| Pulmonary TB             | 376 (49.7%)       | 325 (43.0%) | 25 (3.3%) | 15 (2.0%) | 15 (2.0%) | 756 |
| Extra PTB                | 0 (0.0%)          | 442 (92.1%) | 23 (4.8%) | 0 (0.0%) | 15 (3.1%) | 480 |
| **Patient category**     |                   |           |      |         |           |     |
| New cases                | 352 (29.4%)       | 759 (63.3%) | 46 (3.8%) | 13 (1.1%) | 29 (2.4%) | 1199 |
| Re treatment             | 24 (64.9%)        | 8 (21.6%)  | 2 (5.4%) | 2 (5.4%) | 1 (2.7%) | 37  |
| **Total**                | 376 (30.4%)       | 767 (62.1%) | 48 (3.9%) | 15 (1.2%) | 30 (2.4%) | 1236 |

2.4%, which is in line with the finding in Debre Tabor. However, the majority of previous studies reported that defaulting from TB treatment ranged from 2.8% in Dabat to 30.8% in South West Nigeria [6, 7, 10, 12–16, 18–22, 24, 26, 28, 32]. The lower defaulting rate in our study could be due to better implementation of DOT strategies, including defaulter tracing system, supervision, and health education activities.

The other main problem of TB controlling program is treatment failure. In our study, 1.2% of the TB patients were identified as treatment failure. This figure is lower than the reports from Ibadan Nigeria (8.1%) [21], Egypt (6.25%), Niger delta (4.8%), South West Nigeria (3.8%), Tigray Region (3.7%), and Debre Tabor (3.5%), but it is higher than finding from many studies conducted in different parts of Ethiopia [7, 12–16, 18, 19, 25, 26, 30] which ranged between 0.2% and 0.8%.

Identification of factors associated with treatment outcome of TB patients is very crucial in order to tackle those factors leading to poor treatment outcome. The present study revealed that being female; age greater than 55 years, having
Table 4: Bivariate analysis of treatment outcome with socio-demographic and clinical characteristics of TB patients attending public hospitals of Harar town, Eastern Ethiopia, 2017 (n=1236).

| Characteristics | Treatment outcome | P value | COR (95% CI) |
|-----------------|-------------------|---------|--------------|
|                 | Successful Treatment | Unsuccessful treatment |       |
| Place of residence | 1075 (92.4%) | 89 (7.6%) | 0.516 | 1.00 |
| Rural | 68 (94.4%) | 4 (5.6%) |       | 1.407 (0.502 - 3.947) |
| Sex | 677 (91.6%) | 62 (8.4%) | 0.161 | 1.00 |
| Female | 466 (93.8%) | 31 (6.2%) |       | 1.377 (0.880 - 2.153) |
| Age group | | | | |
| 1 - 14 years | 62 (91.2%) | 69 (8.8%) | ≤ 0.001 | 1.00 |
| 15 - 24 years | 342 (96.3%) | 13 (3.7%) | 0.068 | 0.393 (0.144 - 1.072) |
| 25 - 34 years | 339 (93.4%) | 24 (6.6%) | 0.512 | 0.732 (0.287 - 1.863) |
| 35 - 44 years | 191 (93.2%) | 14 (6.8%) | 0.585 | 0.757 (0.279 - 2.055) |
| 45 - 54 years | 107 (89.9%) | 12 (10.1%) | 0.779 | 1.159 (0.414 - 3.242) |
| 55 - 64 years | 61 (84.7%) | 11 (15.3%) | 0.248 | 1.863 (0.648 - 5.355) |
| >64 years | 41 (75.9%) | 13 (24.1%) | 0.026 | 3.276 (1.153 - 9.313) |
| Pre-treatment weight | | | | |
| < 20 Kg | 18 (81.8%) | 4 (18.2%) | 0.177 | 1.00 |
| 20 - 29 Kg | 27 (90.0%) | 3 (10.0%) | 0.074 | 2.863 (0.902 - 9.084) |
| 30 - 37 Kg | 75 (88.2%) | 10 (11.8%) | 0.576 | 1.432 (0.407 - 5.036) |
| 38 - 54 Kg | 688 (93.2%) | 50 (6.8%) | 0.169 | 1.718 (0.795 - 3.714) |
| >55 Kg | 335 (92.8%) | 26 (7.2%) | 0.793 | 0.936 (0.573 - 1.531) |
| Year of registration | | | | |
| 2011 | 285 (91.3%) | 27 (8.7%) | 0.429 | 1.00 |
| 2012 | 181 (94.8%) | 10 (5.2%) | 0.809 | 0.933 (0.534 - 1.632) |
| 2013 | 185 (93.9%) | 12 (6.1%) | 0.112 | 0.544 (0.257 - 1.152) |
| 2014 | 226 (93.0%) | 17 (7.0%) | 0.213 | 0.639 (0.316 - 1.294) |
| 2015 | 266 (90.8%) | 27 (9.2%) | 0.353 | 0.741 (0.394 - 1.395) |
| HIV status | | | | |
| HIV positive | 232 (82.3%) | 50 (17.7%) | ≤ 0.001 | 1.00 |
| HIV negative | 911 (95.5%) | 43 (4.5%) |       | 4.566 (2.963 - 7.036) |
| Patient category | | | | |
| New cases | 1111 (92.7%) | 88 (7.3%) | 0.169 | 1.00 |
| Re treatment | 32 (86.5%) | 5 (13.5%) | 0.507 (0.193 - 1.333) |
| Type of TB | | | | |
| PTB + | 377 (94.3%) | 23 (5.8%) | 0.188 | 1.00 |
| PTB - | 323 (90.7%) | 33 (9.3%) | 0.253 | 0.730 (0.426 - 1.251) |
| Extra PTB | 443 (92.3%) | 37 (7.7%) | 0.421 | 1.223 (0.749 - 1.998) |

Pretreatment weight of 20 – 29 kg and 38 – 54 kg, being HIV negative, and being new TB patient were independently significantly associated with successful treatment outcome.

As reported by many studies [12, 15, 21, 23, 24, 27, 33], females have had bigger chance of successful TB treatment outcome than males. However, the odds of successful treatment outcome were better for males compared to females in studies conducted in Debre Tabor [11], Southern Region [16], and Tigray Region [6]. This difference might have been related to other variables like severity of the disease, timing of the treatment, adherence to the treatment, and behavioral and socioeconomic characteristics. Since almost all of these studies were based on retrospective document review, they did not take into consideration the effect of those important variables.

The HIV status of the TB patients was one of the factors that were associated with the treatment outcome. Not surprisingly, in this study, the HIV negative patients
Table 5: Multivariate analysis of treatment outcome with socio-demographic and clinical characteristics of TB patients attending public hospitals of Harar town, Eastern Ethiopia, 2017 (n=1236).

| Characteristics       | Treatment outcome |          |          |          |          |          |
|-----------------------|-------------------|----------|----------|----------|----------|----------|
|                       | Successful Treatment | Unsuccessful treatment | P. value | AOR (95%CI) |          |          |
| **Sex**               |                    |          |          |          |          |          |
| Male                  | 677 (91.6%)        | 62 (8.4%) | 0.015    | 1.00     |          |          |
| Female                | 466(93.8%)         | 31 (6.2%) |          |          |          |          |
| **Age group**         |                    |          |          |          |          |          |
| 1 - 14 years          | 62 (91.2%)         | 69 (8.8%) | ≤ 0.001  | 1.00     |          |          |
| 15 - 24 years         | 342(96.3%)         | 13 (3.7%) | 0.367    | 2.138(0.411-11.126) |          |          |
| 25 - 34 years         | 339(93.4%)         | 24 (6.6%) | 0.217    | 2.617(0.545-14.561) |          |          |
| 35 - 44 years         | 191(93.2%)         | 14 (6.8%) | 0.318    | 2.386(0.436-13.009) |          |          |
| 45 - 54 years         | 107(89.9%)         | 12 (10.1%) | 0.098    | 4.243(0.766-23.520) |          |          |
| 55 - 64 years         | 61(84.7%)          | 11 (15.3%) | 0.008    | 10.413(1.860-58.298) |          |          |
| >64 years             | 41(75.9%)          | 13 (24.1%) | ≤ 0.001  | 24.41(4.188-142.331) |          |          |
| **Pre-treatment weight** |                  |          |          |          |          |          |
| < 20 Kg               | 18 (81.8%)         | 4 (18.2%) | 0.035    | 1.00     |          |          |
| 20 - 29 Kg            | 27(90.0%)          | 3 (10.0%) | 0.012    | 11.027(1.658-73.347) |          |          |
| 30 - 37 Kg            | 75 (88.2%)         | 10 (11.8%) | 0.088    | 4.053(0.813-20.192) |          |          |
| 38 - 54 Kg            | 688(93.2%)         | 50 (6.8%) | 0.022    | 2.824(1.167-6.831) |          |          |
| >55 Kg                | 335 (92.8%)        | 26 (7.2%) | 0.612    | 1.151(0.669-1.978) |          |          |
| **HIV status**        |                    |          |          |          |          |          |
| HIV positive          | 232 (82.3%)        | 50 (17.7%) | ≤ 0.001  | 1.00     |          |          |
| HIV negative          | 911(95.5%)         | 43 (4.5%) |          |          |          |          |
| **Patient category**  |                    |          |          |          |          |          |
| Re treatment          | 32 (86.5%)         | 5 (13.5%) | 0.033    | 1.00     |          |          |
| New cases             | 1111 (92.7%)       | 88 (7.3%) |          |          |          |          |
| **Type of TB**        |                    |          |          |          |          |          |
| PTB +                 | 377 (94.3%)        | 23 (5.8%) | 0.415    | 1.00     |          |          |
| PTB -                 | 323 (90.7%)        | 33 (9.3%) | 0.208    | 0.686(0.382-1.233) |          |          |
| Extra PTB             | 443 (92.3%)        | 37 (7.7%) | 0.876    | 0.959(0.566-1.625) |          |          |

had bigger chance of successful TB treatment than the HIV positive ones. This finding is consistent with several previous studies [7, 10, 12, 19, 22, 24, 27, 28].

5. Conclusion and Recommendation

The treatment outcome of the TB patients who received TB treatment at the study area was satisfactory and in line with the WHO target. The treatment outcome was significantly associated with gender, age, pretreatment weight, HIV status, and TB category. Moreover, it was not significantly affected by place of residence, year of treatment, and types of TB.

Based on the findings of this study, we recommend that frequent supportive supervision and health education programs for patients with a high risk of unsuccessful treatment outcome should be carried out. In addition, further prospective studies are needed to identify other potential sociodemographic and behavioral factors that could affect the treatment outcomes of TB patients.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

We declare that we have no competing interests.

Authors’ Contributions

Assefa Tola, Kirubel Minsamo Minshore, Yohanes Ayele, and Abraham Nigussie Mekuria conceived the study, participated in the design, data analysis, and interpretation of the result. Assefa Tola, Kirubel Minsamo Minshore, Yohanes Ayele, and Abraham Nigussie Mekuria were involved in data acquisition and writing the draft manuscript. Assefa Tola, Kirubel Minsamo Minshore, Yohanes Ayele, and Abraham Nigussie Mekuria critically reviewed the manuscript. All authors read and approved the manuscript.
Acknowledgments

We would like to extend appreciations to the individuals who were involved in data collection and those hospitals that willingly gave us all the information we needed without any reservation.

References

[1] M. T. Baysari, K. Oliver, B. Egan et al., “Audit and feedback of antibiotic use: utilising electronic prescription data,” Applied Clinical Informatics, vol. 4, pp. 583–595, 2013.

[2] WHO, “Global Tuberculosis Report,” 2017, 2017.

[3] M. Uplekar, D. Weil, K. Lonroth et al., “WHO’s new end TB strategy,” The Lancet, vol. 385, no. 9979, pp. 1799–1801, 2015.

[4] M. Raviglione and G. Sulis, “Tuberculosis 2015: burden, challenges and strategy for control and elimination,” Infectious Disease Reports, vol. 8, no. 2, 2016.

[5] P. Glaziou, C. Sismanidis, K. Floyd, and M. Raviglione, “Global epidemiology of tuberculosis,” Cold Spring Harbor Perspectives in Medicine, vol. 5, no. 2, Article ID a017798, 2015.

[6] G. Berhe, F. Enquselassie, and A. Aseffa, “Treatment outcome of smear-positive pulmonary tuberculosis patients in Tigray Region, Northern Ethiopia,” BMC Public Health, vol. 12, no. 1, 2012.

[7] M. Biruk, B. Yimam, H. Abrha, S. Biruk, and F. Z. Amdie, “Treatment outcomes of tuberculosis and associated factors in an Ethiopian university hospital,” Advances in Public Health, vol. 2016, Article ID 8504629, 9 pages, 2016.

[8] T. Abebe, “Treatment outcome of tuberculosis and risk factors for poor treatment outcomes at jimma university specialized hospital and ommo-nada trainin health center, South West Ethiopia,” 2013.

[9] Ministry of Health of Ethiopia, Tuberculosis, Leprosy and TB/HIV Prevention and Control Program, Ministry of Health of Ethiopia, Addis Ababa, Ethiopia, 6th edition, 2016.

[10] D. Garedew and G. Nemer, “Treatment outcome of tuberculosis and associated factors at gibmi town health facilities Western Oromia, Ethiopia,” Nursing & Care Open Access Journal, vol. 7, no. 2, 2017.

[11] A. Melese, B. Zeleke, and B. Ewneke, “Treatment outcome and associated factors among tuberculosis patients in Debre Tabor, Northwestern Ethiopia: a retrospective study,” Tuberculosis Research and Treatment, vol. 2016, no. 8, 2016.

[12] D. Tarekegne, M. Jemal, T. Atanaw et al., “Treatment outcome of tuberculosis patients in metema hospital, northwest ethiopia: a four years retrospective study,” Mycobacterial Diseases, vol. 5, no. 4, 2015.

[13] G. Asebe and H. Dissa, “Treatment outcome of tuberculosis patients at gambella hospital, Southwest Ethiopia: three-year retrospective study,” Journal of Infectious Diseases & Therapy, vol. 3, no. 2, 2015.

[14] G. Gebregzabiber, G. Romha, E. Ejeta, G. Asebe, E. Zemene, and G. Ameni, “Treatment outcome of tuberculosis patients under directly observed treatment short course and factors affecting outcome in southern ethiopia: a five-year retrospective study,” PLoS ONE, vol. 11, no. 2, 2016.

[15] T. Zenebea and E. Teferab, “Tuberculosis treatment outcome and associated factors among smear-positive pulmonary tuberculosis patients in Afar, Eastern Ethiopia: a retrospective study,” The Brazilian Journal of Infectious Diseases, vol. 2, no. 6, pp. 635-636, 2016.

[16] M. Muñoz-Sellart, L. E. Cuevas, M. Tumato, Y. Merid, and M. A. Yassin, “Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia,” The International Journal of Tuberculosis and Lung Disease, vol. 14, no. 8, pp. 973–979, 2010.

[17] T. Mohammed, K. Daniel, D. Helamo, and T. Leta, “Treatment outcomes of tuberculosis patients in nigist Eleni Mohammed general hospital, hosanna, southern nations, nationalities and peoples region, Ethiopia: A five year (June 2009 to August 2014) retrospective study,” Archives of Public Health, vol. 75, no. 16, 2017.

[18] M. H. Dangisso, D. G. Datiko, and B. Lindtjorn, “Trends of tuberculosis case notification and treatment outcomes in the sidama zone, southern ethiopia: Ten-year retrospective trend analysis in urban-rural settings,” PLoS ONE, vol. 9, no. 12, 2014.

[19] E. Ejeta, M. Chala, G. Arega et al., “Outcome of tuberculosis patients under directly observed short course treatment in western ethiopia,” The Journal of Infection in Developing Countries, vol. 9, no. 7, pp. 752–759, 2015.

[20] M. El-Shabrawy and D. A. El-Shafei, “Evaluation of treatment failure outcome and its predictors among pulmonary tuberculosis patients in Sharkia Governorate, 2013–2014,” Egyptian Journal of Chest Diseases and Tuberculosis, vol. 66, no. 1, pp. 145–152, 2017.

[21] A. A. Fatiregun, A. S. Ojo, and A. E. Bamgboye, “Treatment outcomes among pulmonary tuberculosis patients at treatment centers in Ibadan, Nigeria,” Annals of African Medicine, vol. 8, no. 2, pp. 100–104, 2009.

[22] O. A. Babatunde, O. E. Elegbede, M. Ayodele, J. O. Fadare, and A. O. Isinjaye, “Factors affecting treatment outcomes of tuberculosis in a tertiary health center in Southwestern Nigeria,” International Review of Social Sciences and Humanities, vol. 4, no. 2, pp. 209–218, 2013.

[23] S. N. Oshi, I. Alobu, K. N. Ukwa, and D. C. Oshi, “Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria,” Epidemiology and Infection, vol. 143, no. 5, pp. 932–942, 2015.

[24] S. M. Liew, E. M. Khoo, B. K. Ho, Y. K. Lee, O. Mimi, and M. Y. Fazlina, “Tuberculosis in Malaysia: predictors of treatment outcomes in a national registry,” International Journal of Tuberculosis and Lung Disease, vol. 19, no. 7, 2015.

[25] M. Endris, F. Moges, Y. Belyhun, E. Woldehana, A. Esmael, and C. Unakal, “Treatment outcome of tuberculosis patients at enfraz health center, Northwest Ethiopia: a five-year retrospective study,” Tuberculosis Research and Treatment, vol. 2014, Article ID 726193, 7 pages, 2014.

[26] B. Getahun, G. Amenia, G. Medhina, and S. Biadgilign, “Treatment outcome of tuberculosis patients under directly observed treatment in Addis Ababa, Ethiopia,” International Journal of Tuberculosis and Lung Disease, vol. 17, no. 5, pp. 521–528, 2013.

[27] S. Khazaei, J. Hassanzadeh, S. Rezaeian et al., “Treatment outcome of new smear positive pulmonary tuberculosis patients in Hamadan, Iran: A registry-based cross-sectional study,” Egyptian Journal of Chest Diseases and Tuberculosis, vol. 65, no. 4, pp. 823–830, 2016.

[28] M. G. Beza, M. T. Wubie, M. D. Teferi, Y. S. Getahun, S. M. Bogale, and S. B. Tefera, “A five years tuberculosis treatment outcome at kolla diba health center, Dembia District, Northwest Ethiopia: a retrospective crosssectional analysis,” Infectious Diseases & Therapy, vol. 1, no. 1, 2013.
[29] FMoH of Ethiopia and Ethiopian Health and Nutrition Research Institute. First Ethiopian National Population Based Tuberculosis Prevalence Survey, Addis Ababa, July 2011.

[30] S. Tadesse and T. Tadesse, “Treatment success rate of tuberculosis patients in Dabat, northwest Ethiopia,” *Health*, vol. 6, no. 5, pp. 306–310, 2014.

[31] I. Ebuenyi, P. Ikuabe, and J. Jumbo, “Treatment Outcome of Tuberculosis at One Year: A Single Centre’s Experience in Niger Delta, Nigeria,” *International Journal of Tropical Disease & Health*, vol. 12, no. 1, pp. 1–6, 2016.

[32] N. A. Ifebunandu and K. N. Ukwaja, “Tuberculosis treatment default in a large tertiary care hospital in urban Nigeria: Prevalence, trend, timing and predictors,” *Journal of Infection and Public Health*, vol. 5, no. 5, pp. 340–345, 2012.

[33] D. Demeke, M. Legesse, and J. Bati, “Trend of tuberculosis and treatment outcomes in gambella region with special emphasize on Gambella regional hospital, Western Ethiopia,” *Mycobacterial Diseases*, vol. 3, no. 2, 2013.